Adults Can Still Receive HPV Vaccine Up To Age 45

Preventive health measures taken during childhood often yield long-term advantages in adulthood. Specifically, receiving the human papillomavirus (HPV) vaccine at ages 11 or 12 provides protection against HPV-related cancers and other diseases later in life. The Centers for Disease Control and Prevention (CDC) advises that individuals aged 9 through 26 should receive the HPV vaccine, noting that catching up is possible until age 26 if the shot was missed earlier.

Vaccine Types and Recommendations

Since late 2016, only one HPV vaccine has been available in the United States: the 9-valent HPV vaccine (9vHPV), manufactured by Merck & Co. under the brand name Gardasil 9. This formulation protects against high-risk HPV types as well as those causing anogenital warts. Previously approved vaccines covered common HPV types, but the 9vHPV offers broader coverage. The FDA, CDC, and American Academy of Pediatrics recommend this vaccine for children and adults vulnerable to HPV.

Dosing Schedules By Age Group

The required dosage depends on the patient's age. For most children aged 9 to 14, the CDC recommends two doses spaced 6 to 12 months apart. A third dose becomes necessary if the initial two doses were administered closer than five months apart. Immunocompromised children, such as those with HIV, also require three doses. Experts suggest vaccinating before sexual activity begins, as early protection is most effective.

Individuals starting the series on or after their 15th birthday must receive three doses over six months. The second dose occurs one to two months after the first, while the third follows six months after the initial injection. Adults aged 27 to 45 are not routinely recommended for vaccination because many have already been exposed to HPV. However, those at high risk for new infections may benefit. Decisions for this age group should involve a consultation with a healthcare provider.

Handling Missed Doses And Intervals

Completing the series requires either two or three visits to a healthcare provider. While adhering to the recommended schedule ensures optimal protection, delays do not necessitate restarting the series. There is no maximum interval between doses; patients simply need to receive the next dose as soon as possible. Conversely, administering doses too close together violates minimum intervals. In a two-dose series, the minimum gap is five months. If the second dose arrives earlier, it must be repeated.

For three-dose series, specific minimum intervals apply: four weeks between the first and second doses, 12 weeks between the second and third, and five months between the first and third. Any dose given sooner than these thresholds requires repetition. Having prior HPV infection does not prevent vaccination, and pre-vaccination testing is not recommended. The vaccine protects against future exposures to types not currently present. Regular cervical cancer screening via Pap smears remains important even for fully vaccinated individuals.

Administration And Side Effects

HPV vaccines are injected into the upper arm. Patients may feel a pinch or quick prick upon needle entry. These shots can be administered alongside other routine vaccinations without compromising effectiveness, though providers typically use different arms. Fainting is a potential side effect, particularly among adolescents. Consequently, children are often advised to sit or lie down during and for 15 minutes after the procedure.

Safety data from trials involving thousands of participants indicate the vaccine is safe, with a low rate of serious side effects and no linked deaths. Common reactions include pain, swelling, and redness at the injection site within days of administration. Some individuals report headaches, nausea, exhaustion, or fever. Researchers attribute fainting associated with adolescent vaccines to the process rather than the substance itself, as similar outcomes occur with other adolescent immunizations.

While generally safe for most people, caution is advised for certain groups. Providers should discuss individual risk factors before administering the vaccine to adults over 26. Ensuring appointments for subsequent doses at the time of the initial visit helps complete the full series. Adherence to spacing guidelines maximizes protective benefits against HPV-related conditions.